2 nd Prague European Days of Internal Medicine. December 1 2, 2016 Hotel Diplomat Prague, Czech Republic FINAL PROGRAMME

2nd Prague European Days of Internal Medicine December 1–2, 2016 Hotel Diplomat Prague, Czech Republic

FINAL PROGRAMME

2

2nd Prague European Days of Internal Medicine December 1–2, 2016 Hotel Diplomat, Prague, Czech Republic

2nd Prague European Days of Internal Medicine

3

December 1–2, 2016 Hotel Diplomat, Prague, Czech Republic

CONTENT WELCOME LETTER

4

GENERAL INFORMATION

6

CONFERENCE SECRETARIAT

6

CONFERENCE VENUE

7

REGISTRATION7 INFORMATION FOR PARTICIPANTS

8

INFORMATION FOR SPEAKERS

9

INFORMATION FOR POSTER PRESENTATION

9

CONFERENCE VENUE FLOORPLAN

10

PROGRAMME AT A GLANCE

11

SCIENTIFIC PROGRAMME THURSDAY, DECEMBER 1, 201612 FRIDAY, DECEMBER 2, 201615 LIST OF POSTERS

20

GENERAL INFORMATION

23

INDUSTRY SUPPORTED SYMPOSIA

24

PARTNERS31

4



5


WELCOME LETTER Dear Colleagues and Friends, Please allow me to cordially welcome you to Prague on behalf of the Organizing Committee of the 2nd Prague European Days of Internal Medicine (PEDIM) Conference. This is my pleasure and honor to inform you, that our meeting is endorsed by the European Federation of Internal Medicine (EFIM) as an official event.

I would also like to express my thanks and appreciation to the medical opinion leaders who graciously accepted our invitation to join the international organizing committee and advisory board. Also, it is my duty to express our thanks to sponsors and partners. Without their help and participation it would be almost impossible to organize such a meeting.

I assure you that we have done our utmost to ensure that your conference is both enlightening and enjoyable. That having been said, it is veritably impossible to organize such an event without encountering a few minor issues along the way. Should any arise, I do hope you will find it possible to overlook them in light of our beautiful “City of a Hundred Spires.“ Prague has a very special atmosphere, which developed out of history, tradition, art, architecture, culture and a sense for the finer things in life. I trust that you will avail yourselves of this opportunity to experience the unique ambience of our city, this year, in addition, in the atmosphere of coming Christmas, in Advent.

A couple years ago, some believed internal medicine to be a dying field; one that had already been superseded by other branches of medicine. This is no longer the case: Internal medicine is not dying.

First and foremost, however, we have convened to deliberate matters pertaining to internal medicine, the very cornerstone of complex, integrated medical care. The objective of this conference is to improve the current state of health care in our countries. At present, it is characterized by an ageing population; metabolic, cardiovascular and other noninfectious disease epidemics. However, new possibilities of treatment are becoming available, and it is our great advantage, that we will have a chance to discuss such a treatment with many opinion leaders. This year, we are focusing on metabolic disorders and cardiology, taking in count the great impact of cardiometabolic risk. However, other disciplines are not omitted as well. General internal medicine is than apparent in all presentations. In addition, the tremendous scientific benefits of plenary lectures, case reports, posters and other presentations will be invaluable.

Just as the mythical phoenix rose from its own ashes, so too has internal medicine and I firmly believe that the 2nd PEDIM will provide more than sufficient evidence to confirm the continuing importance of our discipline. I wish all of you a wonderful stay in Prague and I sincerely hope that PEDIM will prove to be an interesting, productive and unforgettable event for all of us.

Richard Ceska, MD, PhD, FACP, FEFIM Professor of Internal Medicine President of the Czech Society of Internal Medicine Conference President, PEDIM 2016

6



7


GENERAL INFORMATION

CONFERENCE VENUE

Hosted by

Conference Prague European Days of Internal Medicine is being held at the Diplomat Hotel which is located near the city center. It is easily accessible by both public and private transport. Diplomat Hotel Prague Evropská 15, 160 41 Prague 6 Czech Republic Phone: +420 296 559 111 www.diplomathotel-prague.com

In Cooperation with

Endorsed by

REGISTRATION Registration Fees

Conference President Richard Ceska, MD, PhD, FACP, FEFIM Professor of Internal Medicine Chair of the Scientific Committee Jiri Widimsky jr., MD, PhD Professor of Internal Medicine

CONFERENCE SECRETARIAT GUARANT International Na Pankraci 17, 140 21 Prague 4 Czech Republic Phone: +420 284 001 444 Fax: +420 284 001 448 E-mail: [email protected]

Delegates Young Internists (up to 35 years)* *ID to be presented Registration fees include 21 % VAT.

ON-SITE FEE 480 EUR 380 EUR

The Registration Fee Includes: • Attending all Conference Scientific Sessions • Admission to the Exhibition Area and Poster Session • Conference materials • Coffee breaks • Lunch box Registration Opening Hours Wednesday, November 30, 2016 Thursday, December 1, 2016 Friday, December 2, 2016:

17:00–20:00 07:45–18:00 08:00–17:30

8



9


INFORMATION FOR PARTICIPANTS

INFORMATION FOR SPEAKERS

CME Accreditation We are pleased to inform you that 2nd Prague European Days of Internal Medicine was granted 10 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Please come to the Speakers’ Ready Room (Meeting room Paris) at least 2 hours before the beginning of your session. In case your speech has been scheduled for morning session please come to the Speakers’ Ready Room one day before the day of your presentation.

2nd Prague European Days of Internal Medicine is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. 2nd Prague European Days of Internal Medicine is designated for a maximum of 10 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Speakers’ Ready Room Opening Hours Wednesday, November 30, 2016 Thursday, December 1, 2016 Friday, December 2, 2016

INFORMATION FOR POSTER PRESENTATION Poster mounting times Thursday, December 1, 2016

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Poster viewing

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Poster removal times*

Certificate of Attendance CME certificates are to be handed out to participants at the Registration Desk. Certificates are to be handed out only based on completed feedback form. Name Badge Participants receive a name badge. Everyone is requested to wear this badge for all conference activities. In case of loss, a new name badge can be printed for a fee of 30 EUR. Language The official language of the conference is English. Translation is not provided.

17:00–20:00 07:45–18:00 08:00–17:00

Thursday, December 1, 2016 Friday, December 2, 2016

Friday, December 2, 2016

07:45–10:00

10:00–17:45 08:30–17:30

17:30–18:00

*All remaining posters after removal times will be removed and the will not be kept for later collection. Book of Abstracts Book of Abstracts is available online at the conference website www.pedim2016.org

10


CONFERENCE VENUE FLOORPLAN


PROGRAMME AT A GLANCE

Exhibition and Coffee Breaks

Registration

PRAGUE Room (A-B-C)

11

PRAGUE Room (D)

Poster Area

Cloakroom

Speakers’ Ready Room

Organizing Committee

08:45-09:00 09:00–10:30 10:30–11:30 11:30–12:00 12:00–12:30 12:30–13:00 13:00–14:30 14:30–15:30 15:30–15:45 15:45–16:45 16:45–17:45

Thursday, December 1, 2016 PRAGUE Room (A-B-C) PRAGUE Room (D) Opening ceremony Metabolic syndrome and epidemiology Heart failure Coffee break 12:15–13:00 Industry sponsored symposium (see page 24) Young internists Lunch break Lunch break How to implement the knowledge of CVD risk in patients with RA into clinical practice Nephrology 15:00–17:00 ScreenPro FH Symposium Coffee break (focused on modern lipid Fixed combination in internal medicine lowering combo therapy, familial hypercholesterolemia, statin Top stories in internal medicine intolerance and metabolic syndrome) Friday, December 2, 2016 PRAGUE Room (A-B-C)

09:00–10:00

Hypertension

12:30–13:00 13:00–14:00

Stroke: A challenge for internal medicine Coffee break Industry sponsored symposium (see page 24) Lunch break Diabetes

14:00–15:00

Clinical lipidology

15:00–15:15

Coffee break

15:15–16:15

General internal medicine

16:15–17:15 17:15–17:30

Intensive care in internal medicine Closing ceremony

10:00–11:00 11:00–11:30 11:30–12:30

PRAGUE Room (D) Free communication – Varia, Intensive care, Rheumatology and CVD Free communication – General internal medicine Coffee break

Lunch break Free communication – Hypertension Free communication – Metabolic syndrome Coffee break Free communication – Atherosclerosis, Heart failure, Hyperlipidemia and dyslipidemia, Stroke

12


SCIENTIFIC PROGRAMME


13


13:00–14:30

How to implement the knowledge of CVD risk in patients with RA into clinical practice Chair: A. G. Semb (Norway)

08:45–09:00

Opening ceremony R. Češka (Czech Republic), J. Widimský jr. (Czech Republic)

09:00–10:30

Metabolic syndrome and epidemiology Chair: R. Cífkova (Czech Republic)

14:30–15:30 Nephrology Chair: V. Tesař (Czech Republic)

EMPA_REG Outcome and other antidiabetic drugs – the view of nephrologist V. Tesař (Czech Republic), Ch. Wanner (Germany) NOACs in patients with renal impairment J. Vachek (Czech Republic)

15:30–15:45

Coffee break

15:45–16:45

Fixed combination in internal medicine Chairs: M. Banach (Poland), J. Widimský jr. (Czech Republic)

Metabolic surgery effects and post bariatric treatment D. Dicker (Israel) The decrease in CHD mortality in the Czech Republic and its causes R. Cífkova (Czech Republic) Prospective study of Slovak forty-year old population – cardiovascular mortality and morbidity after ten years of follow-up. K. Rašlová (Slovakia) Physical activity in the prevention of cardiovascular disease: is there a J curve? D. Lović (Serbia)

10:30–11:30

Heart failure Chair: J. Murín (Slovakia)

Heart failure – the task for internist. Current pharmacological treatment. J. Murín (Slovakia) Complex approach to the treatment of acute heart failure J. Bělohlávek (Czech Republic)

Fixed combination: A modern approach for better compliance in lipid disorders patients M. Banach (Poland) Fixed combination in hypertension: Gold standard in the treatment J. Widimský jr. (Czech Republic)

16:45–17:45

Top stories in internal medicine Chair: V. Kokorin (Russia)

11:30–12:00

Coffee break

12:00–12:30

Industry sponsored symposium (see page 24)

12:30–13:00

Lunch break

Top stories in internal medicine J. Václavík (Czech Republic) Polypill: Pros and cons M. Mamedov (Russia) Acute coronary syndromes and diabetes mellitus: links and feature V. Kokorin (Russia)

THURSDAY, DECEMBER 1, 2016 PRAGUE room (A-B-C)

Cardiovascular risk evaluation and CVD in patients with RA A. G. Semb (Norway) Management of CV risk and disease in RA S. Rollefstad (Norway) Guidelines for CVD prevention in inflammatory joint diseases T. R. Pedersen (Norway)

14



PRAGUE room (D)

FRIDAY, DECEMBER 2, 2016

12:15–13:00

Young internists Chairs: J. Škrha jr. (Czech Republic), J. Václavík (Czech Republic)

PRAGUE room (A-B-C)

Challenging clinical case J. Václavík (Czech Republic) European education in internal medicine. Recommendation from UEMS. J. Škrha jr. (Czech Republic) Potential use of circulating microRNAs in the clinical practice J. Novák (Czech Republic)

15:00–17:00

ScreenPro FH Symposium New Therapies for Hyperlipidemias in Clinical Practise Focused on FH and other genetically determined HLPs

15:00–15:15 15:15–15:30

Familial hypercholesterolemia – an overview (diagnosis and screening) R. Češka (Czech Republic) Statin intolerance M. Banach (Poland)

15:30–15:45 Coffee break 15:45–16:00 16:00–16:15 16:15–17:00

Severe FH T. Freiberger (Czech Republic) Lp(a) M. Ezhov (Russia) Reports from selected countries

09:00–10:00 Hypertension Chair: J. Widimský jr. (Czech Republic)

Fibromuscular dysplasia in clinical practice: Current experience from the European network. A. Persu (Belgium) Non-pharmacological approach to the therapy of severe hypertension J. Widimský jr. (Czech Republic)

10:00 – 11:00 Stroke: A challenge for internal medicine Chair: M. Táborský (Czech Republic)

Endovascular therapy of acute ischemic stroke P. Widimský (Czech Republic) Prevention of stroke: Current options for risk factors management M. Vrablík (Czech Republic) Atrial fibrillation and stroke M. Táborský (Czech Republic)

11:00–11:30

Coffee break

11:30–12:30

Industry sponsored symposium (see page 24)

12:30–13:00

Lunch break

13:00–14:00 Diabetes Chair: P. Nilsson (Sweden) 13:00–13:25 13:25–13:50 13:50–14:00

Drug treatment of type 2 diabetes P. Nilsson (Sweden) Complications of type 2 diabetes J. Škrha jr. (Czech Republic) Lipid modification in type 1 diabetic patients S. Savla (United Kingdom)

15

16


14:00–15:00

Clinical lipidology Chair: T. Pedersen (Norway)

Lipid lowering in the light of clinical trials T. Pedersen (Norway) Current treatment with lipid lowering drugs R. Češka (Czech Republic) Recent treatment of familial chylomicronemia T. Štulc (Czech Republic)

15:00–15:15

Coffee break

15:15–16:15

General internal medicine Chairs: M. Durusu Tanriover (Turkey), R. Češka (Czech Republic)

15:15–15:40 15:40–16:05 16:05–16:15

Adult vaccination in Europe M. Durusu Tanriover (Turkey) Compliance: The new problem of internal medicine R. Češka (Czech Republic) Thrombotic thrombocytopenic purpura and Hodgkin’s lymphoma – an unlikely connection C. F. G. Canelas (Portugal)

16:15–17:15

Intensive care in internal medicine Chair: K. Cvachovec (Czech Republic)

Intensive care in internal medicine. The view of anesthesiologist. K. Cvachovec (Czech Republic) Hypertensive crisis treatment T. Janota (Czech Republic)

17:15–17:30

Closing ceremony R. Češka (Czech Republic), J. Widimský jr. (Czech Republic)


17


PRAGUE room (D) 09:00–10:00

Free Communication – Varia, Intensive care, Rheumatology and CVD Chairs: E. Belousova (Russia), O. Boeva (Russia)

Varia Digestive tract pathology of patients with gout M. Petrova (Russia)

Intensive care Score in gout patients in Yakutsk M. Petrova (Russia)

Rheumatology and CVD Frequency of Inflammatory Back Pain and Structural Changes of Axial Skeleton in Inflammatory Bowel Disease E. Belousova (Russia) Clinical Predictors of Outcomes in Calcific Aortic Valve Disease O. Boeva (Russia)

10:00–11:00 Free Communication – General internal medicine Chairs: J. Galuszka (Czech Republic), J. Magallanes Gamboa (Spain)

Adverse effects of spironolactone during long-term treatment of resistant arterial hypertension J. Václavík (Czech Republic) Sensitivity and specificity of fecal NGAL in the management of Crohn’s disease patients D. Abdulganieva (Russia) Mitral valve prolapse – the results of 15 years observation O. Nikolin (Russia) Hydration Matters – A Quality Improvement Project for Improving Intravenous fluid prescribing practices and documentation in line with NICE CG174 guidance O. Husain (United Kingdom) Plasma lipidomic profiling in patients with cardiac arrhythmias J. Galuszka (Czech Republic) Determinant factors of the mortality for pneumonia in a service of Internal Medicine J. Magallanes Gamboa (Spain)

11:00–11:30

Coffee break

18


13:00–14:00

Free Communication – Hypertension Chairs: V. Gafarov (Russia), B. Štrauch (Czech Republic)

Can the addition of statins to antihypertensive monotherapy replace combination treatment in some hypertensive patients? D. Nebieridze (Russia) Gender features in risk of hypertension in population with depression in Russia/Siberia: WHO epidemiological program MONICA-psychosocial V. Gafarov (Russia) Home BP telemonitoring system with data transmitted to a physician’s office J. Mužík (Czech Republic) Influence of metabolic syndrome on course of arterial hypertension with the position of evaluation the central aortic pressure and arterial stiffness L. Andreeva (Russia) Patient’s noncompliance with the antihypertensive treatment – a frequent cause of resistant hypertension B. Štrauch (Czech Republic) Descriptive study to evaluate patients with chest pain admitting to Preliminary Care Unit (PCU) D G H Ampara, Sri Lanka N. Hettiarachchi (Sri Lanka)

14:00–15:00

Free Communication – Metabolic syndrome Chairs: M. Szántová (Slovakia), N. Hettiarachchi (Sri Lanka)

The frequency of the main factors of risk for CHD in women in different age groups F. Gasimova (Azerbaijan) Epidemiologic survey of lifestyle factors in Slovak outpatients M. Szántová (Slovakia) A community based study to assess the prevalence of Non Communicable Diseases and their risk factors among rural population of Sri Lanka S. Manilgama (Sri Lanka) Descriptive study to evaluate the risk of Metabolic Syndrome among health staff members at District General Hospital Ampara, Sri Lanka N. Hettiarachchi (Sri Lanka) A community based study to assess the awareness of Non-Communicable Diseases among rural population of Sri Lanka S. Manilgama (Sri Lanka)


15:15–16:15

15:00–15:15 Coffee break

Free Communication – Atherosclerosis, Heart failure, Hyperlipidemia and dyslipidemia, Stroke Chairs: J. Hubáček (Czech Republic), G. Dori (Israel)

Atherosclerosis Analysis of risk factors and characteristics of genetic predisposition and clinical–angiographic manifestations of atherosclerosis in patient with ischemic organ damage without stenotic vascular damage H. Shabalina (Russian Federation) Atherosclerosis and Chronic Kidney Disease E. Moubarak (Lebanon) Internist’s view on the problem of cardiovascular patient’s preparation for operations A. Artemova (Russia)

19

Heart failure Left ventricular end systolic and diastolic volumes and ejection fraction in patients with heart failure and preserved ejection fraction – meta-analysis, graphic presentation and their relation with concentric hypertrophy G. Dori (Israel) Hyperlipidemia and dyslipidemia Common polymorphisms as strong predictors of hypertriglyceridemia in Czech population J. Hubáček (Czech Republic) Stroke Amidolytic activity of haemostasis factors activated from zymogens in plasma under influence of stroke peptide pool T. Katrii (Ukraine)

20


LIST OF POSTERS Atherosclerosis P-01 Serum chemerin and fibroblast growth factor-21 levels in acquired aorta valve stenosis patients J. Lurins, A. Visocka, G. Krievina, V. Mackevics, P. Tretjakovs Diabetes P-02 Can a diabetes affect atherosclerosis? D. Gabrielyan, L. Gabrielyan, M. Ivanov P-03 Gliflozin as a possible cause of severe metabolic disorder – case report M. Protuš, J. Kopecký, E. Uchytilová, P. Wohl P-04 Lipid disorders in patients with diabetic foot – efficacy of therapy and relation to amputation and mortality A. Nemcova, A. Jirkovska, M. Dubsky, R. Bem, V. Fejfarova, V. Woskova, A. Pysna, J. Skibova P-05 Lipid modification in type 1 diabetic patients S. Savla P-06 Prevalence of diabetic neuropathy among patients with type 2 diabetes mellitus Z. S. Akbarov, G. A. Khaidarova, N. N. Maksutova, F. A. Takhirova P-07 The impact of inherited thrombophilia on the effect of cell therapy of critical limb ischemia in diabetic patients M. Dubsky, A. Jirkovska, L. Pagacova, R. Bem, A. Nemcova, V. Fejfarova, A. Pysna, K. Navratil General internal medicine P-08 A Retrospective Study on Poisoning Deaths in District General Hospital (DGH) Ampara, Sri Lanka N. M. Hettiarachchi, S. R. Manilgama, R. Sampath, N. Munaweera, S. Kumara P-09 A Review of Fixed Drug Eruption due to Fluconazole B. Mistry, J. Beecker P-10 Cardiac complications in patients who underwent radical cystectomy M. R. Atabegashvili, D. P. Kotova P-11 Changes in the levels of cytokines in course of autoimmune hepatitis D. R. Akberova, D. I. Abdulganieva, A. K. Odintsova, E. Martynova P-12 Co-existent Miliary Tuberculosis and Non-Hodgkin’s Lymphoma – A Case Report A. Ah-Moye, I. Ferreira, S. Sasikumar P-13 Have electronic drug charts made prescribing intravenous fluids more dangerous? A quality improvement project improving the safety of intravenous prescription and administration using an electronic system M. Geddes-Barton, K. Florman, D. Alexander P-14 Pericardial Effusion: A Cause Beyond the Obvious G. Vasconcelos, C. Couto, T. Esteves Rodrigues, P. Matos, L. Torres, A. Castro, M. Mesquita P-15 Psoriasis – unwanted consequence of anti TNF alpha therapy E. Strujić, S. Aligrudić, D. Pravilović Lutovac


P-16 Rhabdomyolysis and Wernicke-Korsakoff Syndrome – a clinical case J. Andrade, J. Barradas, V. Romão, A. Lemos, A. Monteiro P-17 Secondary failure of etanercept therapy in case of good drug level and anti-drug antibodies absence R. Međedović, E. Strujić, A. Međedović, N. Miketić, D. Pravilović Lutovac P-18 Spontaneous coronary artery dissection I. Simkova P-19 Tuberculosis during infliximab therapy – latent infection activation or unwanted therapy consequence? R. Međedović, E. Strujić, A. Međedović, N. Miketić, D. Pravilović Lutovac P-20 Unrecognized and untreated chronic hypoxia – case report E. Strujić, Z. Vukčević Heart failure P-21 Psychoemotional changes at chronic heart failure S. A. Matskevich, O. A. Barbuk, M. I. Belskaya P-22 The study of neurohumoral factors in patients with chronic heart failure N. A. Nuritdinov, D. D. K. Avezov Hyperlipidemia and dyslipidemia P-23 Associations between equivalent radiation dose and blood lipids A. S. Kerimkulova, A. M. Markabayeva, L. M. Pivina, A. S. Ospanova P-24 Generalized Lipodystrophy as a Rare Cause of Heart Failure I. Refatllari, A. Banushi, S. Husi, F. Toti, A. Goda P-25 The analysis of HDL-cholesterol quantity among middle aged Lithuanian adults S. Kutkienė, Ž. Petrulionienė, A. Laucevičius, J. Staigytė, A. Šaulytė, E. Rinkūniene, V. Dženkevičiūtė P-26 The dynamics of serum lipid profile among middle aged Lithuanian adults with dyslipidemia from 2009 to 2015 S. Kutkienė, Ž. Petrulionienė, A. Laucevičius, J. Staigytė, A. Šaulytė, E. Rinkūnienė, V. Dženkevičiūtė Hypertension P-27 Assessment of factors for adherence to treatment in hypertensive patients L. B. Dyussenova, L. M. Pivina, A. S. Kerimkulova, T. I. Belickina P-28 Blood pressure components and lipids: acquainted traits of cardiovascular disease development E. V. Pello, T. V. Kouznetsova, Y. P. Nikitin, J. A. Staessen P-29 Mortality rates by ethnicity among patients suffering from hypertension A. S. Kerimkulova, V. R. Veber, L. G. Proshina, M. P. Rubanova Intensive care P-30 Ethical aspects of enrolling cardiac arrest victims into a research project T. Sudová, J. Bělohlávek, M. Zvěřová

21

22


Metabolic syndrome P-31 Antihypertensive therapy using two free dosed combination of drugs with calcium channel blocker and angiotensin receptor blocker in patients with metabolic syndrome A. Alyavi, B. Alyavi, J. Uzokov P-32 Correction of infectious-inflammatory process in experimental burn disease of stage septic toxaemia N. M. Chornenka P-33 The Metabolic syndrome and Lipids E. Janeková, J. Babjaková, Ľ. Argalášová Nephrology P-34 Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients-single center experience Z. Dimitrijevic, P. Vesovic, B. Mitic, M. Vucic Rheumatology and CVD P-35 Cardiac Involvement in Systemic Sclerosis M. Lezha, Erv. Rapushi, A. Banushi P-36 Cryoglobulinemic vasculitis in a Systemic Lupus Erythematosus patient Erv. Rapushi, V. Salko, A. Zoto, T. Backa, D. Ruci, L. Nuhaj, A. Perolla, A. Doko, I. Refatllari, Eri. Rapushi P-37 Electrophysiological remodeling of the heart in patients with ankylosing spondylitis L. I. Feiskhanova, A. A. Nigmatyanova, E. Gutieva Stroke P-38 Secondary Prevention Following Acute Ischaemic Stroke or Transient Ischaemic Attack (TIA) in Hospital A. Ah-Moye, S. Y. Lee Varia P-39 P-40 P-41 P-42

A Doctor’s Dilemma Solved by the Patient E. Hasani, I. Refatllari, R. Hasani, A. Banushi Analysis of drug induced liver injury at internal department M. Szantova, Z. Durkovicova, J. Sedlacko Experimental model of an acid esophagus burn and its main clinical biochemical parameters T. V. Koval, T. V. Ishchuk, Y. B. Raetska, O. M. Savchuk Chromosome 15 breakage: A strongly possible cause of both ostium secundum atrial septal defect and acute promyelocytic leukemia in a 22 years old female A. Perolla, A. Banushi, A. Demiraj, A. Babameto P-43 Role of mycobacterium tuberculosis MPT63 and MPT83 antigens in mechanisms of immune cells activation in vitro A. Siromolot, O. Oliinyk, D. Kolibo P-44 The impact of CYP4F2 G1347A genotype on patients` plasma metabolic activity after stent implantation V. Zvikas, V. Tatarunas, V. Skipskis, V. Jakstas, V. Lesauskaite


23


GENERAL INFORMATION Public Transport Prague has a very sophisticated public transport system. The Prague metro is quite new and efficient. At peak times, trains run every 2 or 3 minutes, and during off-peak hours at least every 8 minutes. Taxi Service In the city centre, taxis are easy to take from the street but we strongly recommend you use hotel taxis or to call a taxi by phone through the radio taxi service. We recommend you use following taxi companies: AAA Taxi: +420 14 0 14 Profi Taxi: +420 14 0 15 Insurance The organisers do not accept responsibility for individual medical, travel or personal insurance. All participants are strongly advised to take out their own personal insurance before travelling to the conference. Currency & Banking Czech crown (CZK) is the official currency of the Czech Republic. Exchange of foreign currency is available at Prague international Airport and at most hotels, banks and exchange offi ces throughout the city. International credit cards are accepted for payments in hotels, restaurants and shops. Payment in cash in EUR is also available in some restaurants and shops, please ask for details on-site. You can fi nd the official exchange rates on the website of the Czech National Bank at www.cnb.cz. Shopping Most shops in Prague are open from 9:00 to 18:00, Monday to Saturday. Shops in the city centre are usually open from 9:00 to 21:00, Monday to Sunday. Useful telephone numbers 112 – General Emergency for Europe 150 – Fire 155 – Ambulance 156 – Prague Municipal Police 158 – Police

24


INDUSTRY SUPPORTED SYMPOSIA THURSDAY, DECEMBER 1, 2016 PRAGUE room (A-B-C)

12:00–12:30

MSD symposium Primary prevention of HPV-related diseases T. Fait (Czech Republic)

FRIDAY, DECEMBER 2, 2016 PRAGUE room (A-B-C)

11:30–12:30

Sanofi symposium Management of hyperlipidemia in patients with high / very high cardiovascular risk: role of alirocumab in clinical practice Chair: R. Češka (Czech Republic)

Welcome and introduction R. Češka (Czech Republic) Patient with familial hypercholesterolemia M. Vrablík (Czech Republic) Patient with acute coronary syndrome and hypercholesterolemia J. Murín (Slovakia) Diabetic patient with mixed dislipidemia M. Haluzík (Czech Republic)

jako ignorovat jeho vysoký LDL-cholesterol!

Česká tradice

1883 Česká tradice 1883 od roku od roku

1

Reference: 1. SPC Zoletorv. Zkrácená informace o léčivém přípravku Zoletorv® 10 mg / 10 mg, 10 mg / 20 mg, 10 mg / 40 mg, 10 mg / 80 mg potahované tablety (Jedna tableta obsahuje ezetimibum 10 mg a atorvastatinum 10, 20, 40 nebo 80 mg).Indikace: Prevence kardiovaskulárních příhod – přípravek Zoletorv je indikován ke snížení rizika kardiovaskulárních příhod u pacientů s ischemickou chorobou srdeční (ICHS) a s anamnézou akutního koronárního syndromu (AKS), bez ohledu na to, zda předtím byli léčeni statinem. Hypercholesterolémie – jako přídatná terapie k dietě u pacientů s primární hypercholesterolémií nebo smíšenou hyperlipidémií, kde je vhodné použití kombinovaného přípravku: u pacientů, kteří nejsou samotným statinem dostatečně kontrolováni a u pacientů, kteří se již léčí statinem a ezetimibem. Dále jako přídatná terapie k dietě u homozygotní familiární hypercholesterolémie (HoFH). Dávkování a způsob podání: Tablety se podávají jednou denně perorálně, kdykoliv během dne, s jídlem nebo bez něj. Hypercholesterolémie a/nebo ischemická choroba srdeční (s AKS v anamnéze) – 10/10 mg/den až 10/80 mg/den. Obvyklá dávka je 10/10 mg jednou denně. Dávku přípravku Zoletorv je nutno individuálně upravit. Úprava dávky, pokud je zapotřebí, se musí provádět s odstupem minimálně 4 týdnů. Homozygotní familiární hypercholesterolémie – dávka přípravku Zoletorv je 10/10 až 10/80 mg denně. Současné podávání s jinými léčivými přípravky: Zoletorv je nutno podávat ≥ 2 hodiny před nebo ≥ 4 hodiny po podání sekvestrantu žlučových kyselin. U starších pacientů není nutno dávku upravovat. Bezpečnost a účinnost přípravku Zoletorv u dětí nebyla stanovena. Přípravek Zoletorv se u pacientů s poruchou funkce jater musí podávat opatrně. U pacientů s poruchou funkce ledvin není nutno dávku upravovat. Kontraindikace: Hypersenzitivita na léčivou látku(y) nebo na kteroukoli pomocnou látku. Těhotenství a kojení. Aktivní onemocnění jater nebo nevysvětlené přetrvávající zvýšení sérových transamináz přesahující 3násobek horního limitu normálu. Přípravek Zoletorv je kontraindikován u žen ve fertilním věku, pokud nepoužívají účinnou antikoncepci. Zvláštní upozornění a opatření pro použití: Myopatie/rhabdomyolýza: V rámci zkušeností s ezetimibem po jeho uvedení na trh byly hlášeny případy myopatie a rhabdomyolýzy. Většina pacientů, u nichž došlo k rozvoji rhabdomyolýzy, užívala statin současně s ezetimibem. U pacientů s predispozicí k rhabdomyolýze je nutno předepisovat přípravek Zoletorv opatrně. Všechny pacienty, u nichž se zahajuje léčba přípravkem Zoletorv nebo se dávka zvyšuje, je nutno poučit o riziku myopatie a upozornit je na nutnost okamžitě ohlásit jakoukoli nevysvětlenou svalovou bolest nebo slabost. Pokud jsou koncentrace CK zvýšeny nad 5násobek ULN, nelze léčbu zahájit. Pokud jsou svalové příznaky závažné a způsobují každodenní dyskomfort, i když jsou hladiny CK zvýšeny ≤ 5násobek ULN, je nutno zvážit vysazení léčby. Přípravek Zoletorv se musí vysadit, pokud dojde ke klinicky významnému zvýšení hladin CK (> 10násobek horního limitu normálu) nebo pokud je diagnostikována rhabdomyolýza nebo je na ni podezření. Jaterní enzymy: v kontrolovaných studiích souběžného podávání u pacientů léčených ezetimibem a atorvastatinem byla pozorována po sobě jdoucí zvýšení transamináz. Testy jaterních funkcí je nutno provést před zahájením léčby a poté je nutno je provádět pravidelně. Pokud zvýšení transamináz o více než 3násobek horní hranice normálu přetrvává, doporučuje se snížení dávky nebo vysazení přípravku Zoletorv. U pacientů se středně závažnou nebo závažnou jaterní nedostatečností se přípravek Zoletorv nedoporučuje. U pacientů s předchozí hemoragickou cévní mozkovou příhodou nebo lakunárním infarktem je poměr rizik a přínosů atorvastatinu v dávce 80 mg nejistý, přičemž potenciální riziko hemoragické cévní mozkové příhody je nutno před zahájením léčby pečlivě uvážit. V případě podezření, že se u pacienta vyvinula intersticiální plicní nemoc, musí být léčba statinem vysazena. Interakce s jinými léčivými přípravky a jiné formy interakce: Současné podávání přípravku Zoletorv a fibrátů se nedoporučuje. Při zahajování léčby přípravkem Zoletorv u pacientů léčených cyklosporinem je nutno postupovat opatrně a během léčby je nutno sledovat koncentrace cyklosporinu. V případech, kdy se přípravek Zoletorv přidá k warfarinu, jinému kumarinovému antikoagulanciu nebo fluindionu, je nutno sledovat INR. Atorvastatin se nesmí podávat současně se systémovou léčbou kyselinou fusidovou nebo během 7 dnů po ukončení léčby kyselinou fusidovou. Současné podávání s léčivými přípravky, které mohou zvyšovat plazmatické koncentrace atorvastatinu, jako jsou silné inhibitory CYP3A4 nebo transportních proteinů, může zvyšovat riziko rhabdomyolýzy. Riziko myopatie může být zvýšeno při současném podávání gemfibrozilu a dalších derivátů kyseliny fibrové, bocepreviru, erythromycinu, niacinu, telapreviru nebo kombinace tipranavir/ritonavir. Dále viz úplné znění SPC. Nežádoucí účinky: Jako časté byly hlášeny průjem a myalgie. Pro úplnou informaci se seznamte s plným zněním SPC. Zvláštní opatření pro uchovávání: Uchovávejte v původním obalu, aby byl přípravek chráněn před kyslíkem. Druh obalu a velikost balení: Zoletorv 10 mg / 10 mg, 10 mg / 20 mg, 10 mg / 40 mg a 10 mg / 80 mg. Balení po 10, 30, 90 a 100 potahovaných tabletách v dusíkem profouknutých Al/Al blistrech (dutina z oPA-Al-PVC s víčkem z Al). Balení po 30x 1 a 45x 1 potahovaných tabletách v jednodávkových dusíkem profouknutých Al/Al blistrech (dutina z oPA-Al-PVC s víčkem z Al). Na trhu nemusí být všechny velikosti balení. Držitel rozhodnutí o registraci: Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Velká Británie. Registrační čísla: 31/403–406/14-C. Poslední revize textu: 12. 4. 2016. Dříve než přípravek předepíšete, seznamte se, prosím, s úplným souhrnem údajů o přípravku. Tento přípravek je vázán na lékařský předpis a je částečně hrazen z prostředků veřejného zdravotního pojištění. POUZE PRO ODBORNOU VEŘEJNOST. © Copyright Merck Sharp & Dohme s.r.o., 2016. Všechna práva vyhrazena. Merck Sharp & Dohme s.r.o., Evropská 2588/33a, 160 00 Praha 6, Česká republika Tel.: +420 233 010 111, e-mail: [email protected], www.msd.cz

08-2017-CARD-1193660-0000

130 let ve službách zdraví

130 let ve službách zdraví

28


NOTES


29

30



31


PARTNERS The organizing committee would like to thank conference partners for their strong support! Gold Partner

Silver Partners

Partner

CONFERENCE SECRETARIAT GUARANT International Na Pankráci 17 140 21 Prague 4 Czech Republic Phone: +420 284 001 444 Fax: +420 284 001 448 E-mail: [email protected]

WWW.PEDIM2016.ORG

2 nd Prague European Days of Internal Medicine. December 1 2, 2016 Hotel Diplomat Prague, Czech Republic FINAL PROGRAMME

Recommend Documents